Lilly, Teva Clash on Time Left in Trial on Rival Migraine Drugs

Eli Lilly & Co. and Teva Pharmaceuticals Industries Ltd., in the midst of a patent-infringement trial over competing migraine treatments, each accused the other of hogging the allotted time and urged a federal judge to reject its rival’s proposed timing for sending the case to a Massachusetts jury.

Both Teva’s Ajovy and Lilly’s Emgality use human monoclonal antibodies—fremanezumab and galcanezumab, respectively—to target a molecule linked to migraines. Lilly has conceded Emgality directly infringes three Teva patents, but jurors will determine whether Lilly induces or contributes to infringement by third parties.

The trial, which began Oct. 18 in Boston, is ...